Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 14,504 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 14,504 · Balance 14,504 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 31,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 13, 2023 21:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 86,668 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001437749-23-017297 · rdgdoc.xml · derivative · entry 5 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 86,668 shares Expires 2027-06-09 Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 86,668 | $2.05 | $177,669.40 |
DisclosureSEC source: 0001437749-23-017297 · rdgdoc.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,915 Read SEC document |
| June 09, 2023 Filed Jul 7, 2023 00:30 UTC Amendment | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 86,668 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001437749-23-019535 · rdgdoc.xml · derivative · entry 5 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 86,668 shares Expires 2027-06-09 Read SEC document |
| June 09, 2023 Filed Jul 7, 2023 00:30 UTC Amendment | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 86,668 | $2.05 | $177,669.40 |
DisclosureSEC source: 0001437749-23-019535 · rdgdoc.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528,836 F1 · balance_after: The number of shares beneficially owned, as reported on the Form 4 filed on June 13, 2023, erroneously included options held by the Reporting Person. Read SEC document |
| May 25, 2023 Filed Jun 6, 2023 23:28 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,168 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-016803 · rdgdoc.xml · derivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,168 Underlying: Common Stock · 20,168 shares Expires 2033-05-25 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2023. Read SEC document |
| May 25, 2023 Filed Jun 6, 2023 23:28 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-016803 · rdgdoc.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 25, 2023. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 02:31 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 6,748,629 | $1.05 | $7,086,060.45 |
DisclosureSEC source: 0001599298-23-000028 · wf-form4_167832905731524.xml · nonDerivative · entry 3 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 9,884,095 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 02:31 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 804,672 | $1.05 | $844,905.60 |
DisclosureSEC source: 0001599298-23-000028 · wf-form4_167832905731524.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 1,178,529 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 02:31 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 15,973,743 | $1.05 | $16,772,430.15 |
DisclosureSEC source: 0001599298-23-000028 · wf-form4_167832905731524.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,395,269 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| March 08, 2023 Filed Mar 13, 2023 22:27 UTC Amendment | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 6,748,629 | $1.05 | $7,086,060.45 |
DisclosureSEC source: 0001387131-23-003381 · zangeneh-form4a_030823.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Co-CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 9,884,095 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 13, 2023 22:27 UTC Amendment | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 16,778,415 | $1.05 | $17,617,335.75 |
DisclosureSEC source: 0001387131-23-003381 · zangeneh-form4a_030823.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 24,573,798 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F2 · shares: Includes the number of shares of Common Stock that were inadvertently previously disclosed as being held by Dr. Zanganeh personally, which are held by the Mahkam Zanganeh Revocable Trust. Dr. Zanganeh does not directly hold any shares personally, all of her shares are held through the Mahkam Zanganeh Revocable Trust. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 06, 2022 Filed Dec 9, 2022 23:22 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 373,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-22-012291 · zangeneh-form4_120622.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,930,849 F1 · kind: 373,857 shares of Common Stock were issued to the Reporting Person as payment of interest in connection with a Note Purchase Agreement, dated December 6, 2022, by and among the Issuer, the Reporting Person and Robert W. Duggan. The determination of the number of shares of Common Stock to be issued to the Reporting Person was based on a per share price of $0.79. F1 · price: 373,857 shares of Common Stock were issued to the Reporting Person as payment of interest in connection with a Note Purchase Agreement, dated December 6, 2022, by and among the Issuer, the Reporting Person and Robert W. Duggan. The determination of the number of shares of Common Stock to be issued to the Reporting Person was based on a per share price of $0.79. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:36 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 1,030,925 | $0.97 | $999,997.25 |
DisclosureSEC source: 0001387131-22-008886 · zangeneh-form4_081622.xml · nonDerivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director · Co-CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 3,135,466 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:36 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 4,593,777 | $0.97 | $4,455,963.69 |
DisclosureSEC source: 0001387131-22-008886 · zangeneh-form4_081622.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director · Co-CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 7,061,557 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:36 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 184,430 | $0.97 | $178,897.10 |
DisclosureSEC source: 0001387131-22-008886 · zangeneh-form4_081622.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director · Co-CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,969 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:59 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 86,668 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001387131-22-006923 · zangeneh-form4_060922.xml · derivative · entry 5 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,668 Underlying: Common Stock · 86,668 shares Expires 2027-06-09 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:59 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 86,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-22-006923 · zangeneh-form4_060922.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,168 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. Read SEC document |
| May 19, 2022 Filed May 24, 2022 00:52 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 56,075 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-22-064002 · tm2216672-2_4seq1.xml · derivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,075 Underlying: Common Stock · 56,075 shares Expires 2032-05-19 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on August 19, 2022. Read SEC document |
| May 19, 2022 Filed May 24, 2022 00:52 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-22-064002 · tm2216672-2_4seq1.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 19, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:16 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001599298-21-000039 · wf-form4_163977578709580.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-12-15 F2 · price: (2) Not applicable. F1 · derivative.exercise_date: (1) The option was granted on December 15, 2021. The shares underlying the option are scheduled to vest on December 15, 2024 (the three-year anniversary of the grant date). Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 8,026 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035015 · doc4.xml · derivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,026 Underlying: Common Stock · 8,026 shares Expires 2031-05-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035015 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:37 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 389,077 | $5.24 | $2,038,763.48 |
DisclosureSEC source: 0000921895-21-001334 · form412566zan_05142021.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 2,643,319 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 307 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001209191-21-004669 · doc4.xml · derivative · entry 6 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 0 Underlying: Common Stock · 307 shares Expires 2025-06-15 Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 307 | $7.01 | $2,152.07 |
DisclosureSEC source: 0001209191-21-004669 · doc4.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 107,074 Read SEC document |
| January 08, 2021 Filed Jan 21, 2021 21:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 3,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001209191-21-004669 · doc4.xml · derivative · entry 5 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2025-06-15 Read SEC document |
| January 08, 2021 Filed Jan 21, 2021 21:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 3,000 | $7.01 | $21,030.00 |
DisclosureSEC source: 0001209191-21-004669 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,500 Read SEC document |
| November 22, 2020 Filed Nov 24, 2020 23:12 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 2,400,000 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0000921895-20-003108 · form412566zan_11242020.xml · derivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,724,499 Underlying: Common Stock · 2,400,000 shares Expires 2030-11-22 F1 · price: The option was granted on November 22, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 22, 2021, subject to the satisfaction of certain performance targets. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:25 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 3,323 | Not disclosed Strike: $3.71 | Not disclosed |
DisclosureSEC source: 0000921895-20-002948 · form412566001_11132020.xml · derivative · entry 4 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,324,500 Underlying: Common Stock · 3,323 shares Expires 2030-11-11 F2 · price: The option was granted on November 11, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in full on December 31, 2020. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:25 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $3.71 | Not disclosed |
DisclosureSEC source: 0000921895-20-002948 · form412566001_11132020.xml · derivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,321,177 Underlying: Common Stock · 200,000 shares Expires 2030-11-11 F1 · price: The option was granted on November 11, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 11, 2021. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,193 | $10.70 | $12,767.13 |
DisclosureSEC source: 0001209191-20-038948 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 106,767 F1 · kind: The Reporting Person's immediate family member received the shares from a banking institution as resolution to an error made by the institution in connection with a subscription order placed for the Issuer's rights offering. Such shares were not acquired directly from the Issuer. F2 · price: This is the weighted average purchase price of the shares, which ranged from $10.69 to $10.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:22 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 7,950 | $7.01 | $55,729.50 |
DisclosureSEC source: 0001209191-20-037928 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 105,574 F1 · kind: The Reporting Person's immediate family member acquired the shares from a banking institution due to an error by such institution in connection with subscriptions for the Issuer's rights offering. Such shares were not acquired from the Issuer. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 307 | Not disclosed Strike: $7.01 | Not disclosed |
DisclosureSEC source: 0001209191-20-037234 · doc4.xml · derivative · entry 6 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 307 Underlying: Common Stock · 307 shares Expires 2025-06-15 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 3,000 | Not disclosed Strike: $7.01 | Not disclosed |
DisclosureSEC source: 0001209191-20-037234 · doc4.xml · derivative · entry 5 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2025-06-15 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 2,050 | $7.01 | $14,370.50 |
DisclosureSEC source: 0001209191-20-037234 · doc4.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 97,624 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 20,000 | $7.01 | $140,200.00 |
DisclosureSEC source: 0001209191-20-037234 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,500 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| May 18, 2020 Filed May 19, 2020 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 14,071 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-20-030682 · doc4.xml · derivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,071 Underlying: Common Stock · 14,071 shares Expires 2030-05-18 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 18, 2020 Filed May 19, 2020 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-20-030682 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 9,210 | $0.00 Strike: $13.03 | $0.00 |
DisclosureSEC source: 0001209191-19-030902 · doc4.xml · derivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,210 Underlying: Common Stock · 9,210 shares Expires 2029-05-16 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.03 | $0.00 |
DisclosureSEC source: 0001209191-19-030902 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 2,364 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-19-003042 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,364 Underlying: Common Stock · 2,364 shares Expires 2029-01-07 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the date of the Issuer's Annual Meeting to be held in 2019, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 23, 2018 Filed May 24, 2018 22:41 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001209191-18-033158 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:19 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,100 | $23.98 | $26,378.00 |
DisclosureSEC source: 0001209191-17-065914 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 95,574 Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 01:30 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,000 | $23.98 | $23,979.00 |
DisclosureSEC source: 0001209191-17-065525 · doc4.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 94,474 F2 · price: This is the weighted average purchase price of the shares, which ranged from $23.92 to $24.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 11, 2017 Filed Dec 14, 2017 01:30 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 3,000 | $22.76 | $68,289.00 |
DisclosureSEC source: 0001209191-17-065525 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 93,474 F1 · price: This is the weighted average purchase price of the shares, which ranged from $22.59 to $22.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $23.08 | $0.00 |
DisclosureSEC source: 0001209191-17-059432 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-11-02 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option will vest on February 9, 2018, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 01:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 7,775 | $15.02 | $116,790.61 |
DisclosureSEC source: 0001209191-17-053234 · doc4.xml · nonDerivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,500 F3 · price: This is the weighted average purchase price of the shares, which ranged from $14.68 to $15.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 19, 2017 01:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 9,000 | $13.55 | $121,937.40 |
DisclosureSEC source: 0001209191-17-053234 · doc4.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,725 F2 · price: This is the weighted average purchase price of the shares, which ranged from $12.9397 to $13.88 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 19, 2017 01:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 13,000 | $12.23 | $158,941.90 |
DisclosureSEC source: 0001209191-17-053234 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,725 F1 · price: This is the weighted average purchase price of the shares, which ranged from $11.8658 to $12.5499 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 21:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 5,000 | $23.00 | $115,015.00 |
DisclosureSEC source: 0001209191-17-047762 · doc4.xml · nonDerivative · entry 4 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 90,474 F4 · price: This is the weighted average purchase price of the shares, which ranged from $22.78 to $23.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.